Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
BMC Cancer|April 19, 2013
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapyTracy R Daniels-Wells, Gustavo Helguera, Richard K Leuchter, et al.Expert Review of Anticancer Therapy|March 11, 2005
Monoclonal antibody therapy of ovarian cancerChristopher F Nicodemus, Jonathan S BerekCancer Immunology, Immunotherapy : CII|December 6, 2017
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumorsKamiya Mehla, Jarrod Tremayne, James A Grunkemeyer, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Christopher F NicodemusAmerican Journal of Obstetrics and Gynecology|January 19, 2010
Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapyChristopher F Nicodemus, Lin Wang, Julie Lucas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancerJonathan Berek, Peyton Taylor, William McGuire, et al.The American Journal of Pathology|February 4, 2014
Discordant biological and toxicological species responses to TLR3 activationWilliam M Mitchell, Christopher F Nicodemus, William A Carter, et al.Molecular Cancer Therapeutics|November 8, 2018
Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic CancerAmanda MacDonald, Michelle Priess, Jennifer Curran, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2009
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancerPatricia Braly, Christopher F Nicodemus, Christina Chu, et al.American Journal of Clinical Oncology|September 13, 2019
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic AdenocarcinomaChi Lin, Vivek Verma, Audrey Lazenby, et al.Pageof 3